Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.
- Revenue in USD (TTM)34.86bn
- Net income in USD-563.00m
- LocationBristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
- Phone+1 (212) 546-4000
- Fax+1 (302) 655-5049
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|BMY:NYQ since |
|MyoKardia Inc||Announced||05 Oct 2020||05 Oct 2020Announced||1.62%||13.77bn|
|Formation Biologics Corp||Deal completed||24 Aug 2020||24 Aug 2020Deal completed||-4.05%||--|